Alpha Bioventure partners with nonprofit hospitals, healthcare systems and other organizations, in order to guide
foundations' process. We connect healthcare fundraisers with each other (including outside experts) to bring
the best solutions for your health projects. Whether you are a seasoned professional, just entering the field,
or providing support to the fundraising effort, Alpha Bioventure is the leadership in modern healthcare investing
development.
Founding Partner
Bo Liang, Ph.D., MBA
-
2015 Founded IVIEW Therapeutics Inc., which focuses on developing ophthalmological and wound care
medications. Its Iview-1201 for ophthalmic medication will begin phase II trials in 2018.
-
2010 Established Adesso Advanced Materials, which successfully developed revolutionary re-workable
and recyclable epoxy resin systems and won JEC ASIA Innovation Award in 2012 and TechConnect World Innovation
Award in 2016.
- He was Executive Vice President of Foresight Biotherapeutics, Inc. (New York). The eye medicine invented
by him was acquired by Shire pharmaceuticals in 2015 for $300 million after clinical phase II.
-
2006 Co-founded CLS Pharmaceuticals with two American ophthalmologist, advanced an ophthalmic
drug project into clinical phase II and successfully transferred it to Foresight Biotherapeutics.
- Co-Founder of Sino-American Pharmaceutical Professionals Association- Greater Philadelphia (SAPA-GP), also
the first President of SAPA-GP from 2001 to 2003.
- Former senior R&D scientist of Pharmacopeia, responsible for drug development and advancing drug candidates
into clinic phase. The first-in-class nasal decongestant created by him entered clinical phase II.
- Holds over 40 issued United States, China and international patents.
- Bachelor of chemistry, Peking University; Ph.D. in chemistry, University of Pennsylvania; MBA, the NYU Stern
School of Business.
Team Advantages
A wide range of network resources in the pharmaceutical industry, including China and the United States.
Our laboratory can pre-hatch quickly to shorten the return on investment cycle.
Management team has a wealth of experience in the biopharmaceutical industry operations, and is an effective
guidance on investment projects.
Relying on the top professional advisory team of the US-China Development Association to ensure a high return
on investment.
Our Special Resources:
- Founding team’s successful entrepreneurial track record
- Strong connection with Pennsylvania Biotechnology center, premier universities and biotech parks in the tri-state
area
- Successful experience with US government funding sources such as NIH SBIR
- Strong connection with Sino-American Pharmaceutical Association (SAPA)
